With the key focus on research and pharmaceutical development of innovative therapies based on mesenchymal stem cells (MSC), apceth Biopharma’s product pipeline makes full use of:

  • the full potential of our modular proprietary platform for the genetic engineering of MSC;
  • the inherent regenerative and immunomodulatory potential of unmodified MSC.

In this way, apceth Biopharma is creating a pioneering pipeline of clinical and preclinical stage products comprising both engineered and native MSC.
Our products are based primarily on donor-derived allogeneic MSC and, to a smaller extent, on patients’ own autologous MSC.